Skip NavigationSkip to Content
Return Return to Search Results

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

  1. Author:
    Gardner, E. R.
    Burger, H.
    van Schaik, R. H.
    van Oosterom, A. T.
    de Bruijn, E. A.
    Guetens, G.
    Prenen, H.
    de Jong, F. A.
    Baker, S. D.
    Bates, S. E.
    Figg, W. D.
    Verweij, J.
    Sparreboom, A.
    Nooter, K.

  2. Author Address

    SAIC Frederick, Clin Pharmacol Res Core, Frederick, MD USA. Erasmus Univ, Med Ctr, Dept Med Oncol,Josephine Nefkens Inst, Erasmus MC,Daniel den Hoed Canc Ctr, Rotterdam, Netherlands. Erasmus Univ, Med Ctr, Dept Clin Chem, Rotterdam, Netherlands. Univ Louvain, Dept Oncol, Louvain, Belgium. Univ Antwerp, Dept Chem, B-2020 Antwerp, Belgium. Univ Antwerp, Dept Med Oncol, B-2020 Antwerp, Belgium. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. NCI, Med Oncol Branch, Bethesda, MD 20892 USA. NCI, Clin Pharmacol Res Core, Bethesda, MD 20892 USA.;Sparreboom, A, St Jude Childrens Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.;Alex.Sparreboom@stjude.org
    1. Year: 2006
    2. Date: Aug
  2. Journal: Clinical Pharmacology & Therapeutics
    1. 80
    2. 2
    3. Pages: 192-201
  4. Type of Article: Article
  5. ISSN: 0009-9236
  1. Abstract:

    Objective: Our objective was to explore the relationships between imatinib pharmacokinetics and 9 allelic variants in 7 genes coding for adenosine triphosphate-binding cassette transporters (ABCB1 and ABCG2) and enzymes (cytochrome P450 [CYP] 2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) of putative relevance for imatinib. Methods. Imatinib transport in vitro was studied by use of human embryonic kidney 293 cells transfected with wild-type ABCG2 and an ABCG2 Q141K clone. Steady-state pharmacokinetics of imatinib was obtained in 82 patients with gastrointestinal stromal tumors treated with oral imatinib at doses ranging from 100 to 1000 mg/d. Genotyping was carried out via direct sequencing or restriction fragment length polymorphism-based techniques. Results. Human embryonic kidney 293 cells transfected with ABCG2 Q141K exhibited greater drug accumulation in vitro in comparison with cells expressing wild-type ABCG2 (P = .028). However, pharmacokinetic parameters of imatinib in vivo were not statistically significantly different in 16 patients who were heterozygous for ABCG2 421C > A compared with 66 patients carrying the wild-type sequence (P = .479). The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695). Pharmacokinetic parameters were not related to any of the other multiple-variant genotypes (P >= .230), possibly because of the low allele frequencies. Conclusions. This study indicates that common genetic variants in the evaluated genes have only a limited impact on the pharmacokinetics of imatinib. Further investigation is required to quantitatively. assess the clinical significance of homozygous variant ABCG2 and CYP2D6 genotypes in patients treated with imatinib.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.clpt.2006.05.003
  3. View record in Web of Science®
  4. WOS: 000239794800009

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel